Amylyx Pharmaceuticals (AMLX) Gross Margin (2022 - 2024)

Amylyx Pharmaceuticals' Gross Margin history runs 3 years deep, the most recent figure standing at 100.0% for Q4 2024.

• On a quarterly basis, Gross Margin rose 863.0% year-over-year to 100.0% in Q4 2024; TTM through Sep 2025 was 100.0%, a 771.0% increase from a year earlier, with the FY2024 full-year figure at 93.19%, down 13.0% from the prior year.
• Gross Margin held at 100.0% in Q4 2024 per AMLX's latest filing, from 100.0% in the prior quarter.
• Across five years, Gross Margin topped out at 100.0% in Q3 2024 and bottomed at 50.14% in Q3 2022.
• The 3-year median for Gross Margin is 93.81% (2023), against an average of 90.3%.
• Across the five-year window, Gross Margin surged 4477 bps in 2023 and soared 69 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 87.11% in 2022, then advanced by 5 bps to 91.37% in 2023, then climbed by 9 bps to 100.0% in 2024.
• Per Business Quant, the three latest AMLX Gross Margin figures stand at 100.0% (Q4 2024), 100.0% (Q3 2024), and 99.22% (Q2 2024).